MYLAN 2250 MYLAN 2250 (Mycophenolate mofetil 250 mg)
Pill imprint MYLAN 2250 MYLAN 2250 has been identified as Mycophenolate mofetil 250 mg.
Mycophenolate mofetil is used in the treatment of nephrotic syndrome; systemic lupus erythematosus; dermatomyositis; organ transplant, rejection prophylaxis; rheumatoid arthritis (and more), and belongs to the drug class selective immunosuppressants. There is positive evidence of human fetal risk during pregnancy. Mycophenolate mofetil 250 mg is not a controlled substance under the Controlled Substance Act (CSA).
- MYLAN 2250 MYLAN 2250
- 250 mg
- Tan / Purple
- 19.00 mm
- Prescription only
- Drug Class:
- Selective immunosuppressants
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Mylan Pharmaceuticals Inc.
- National Drug Code (NDC):
- Inactive Ingredients:
- silicon dioxide
sodium lauryl sulfate
FD&C Blue No. 2
ferric oxide red
ferric oxide yellow
|NDC Code||Manufacturer / Repackager|
|51079-0721||UDL Laboratories Inc|
Note: Inactive ingredients may vary.
More about mycophenolate mofetil
- Mycophenolate mofetil
- Mycophenolate mofetil capsules
- Mycophenolate mofetil solution
- Mycophenolate mofetil suspension
- Mycophenolate Intravenous (Advanced Reading)
- Mycophenolate mofetil (Advanced Reading)
- Other brands: CellCept
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.